NMN

NMN (β-nicotinamide mononucleotide) is a nucleotide derived from ribose and nicotinamide. It is the immediate precursor to NAD+ in the NAD+ salvage pathway — one step upstream of NAD+ itself. In cells, NMN is converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase).

The synthesis of NMN from nicotinamide is catalysed by NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway. NAMPT expression and activity decline with age, contributing to the well-documented ~50% fall in NAD+ levels between ages 40 and 60. NMN supplementation bypasses this bottleneck by providing NMN directly.

Human trials confirm that oral NMN raises blood NAD+ concentrations in a dose-dependent manner. The landmark 2021 Yoshino et al. paper (Science) showed that NMN improved skeletal muscle insulin signalling and NAD+ metabolomics in premenopausal women with prediabetes — the first human trial to demonstrate tissue-level metabolic benefits. NMN is now one of the most widely used longevity supplements globally.

// DIRECT NAD+ PRECURSOR

NMN enters cells via the Slc12a8 transporter (and possibly other routes) and is converted to NAD+ by NMNAT1/2/3. This single enzymatic step makes NMN the most efficient oral NAD+ precursor — one step versus two steps for NR (which must first be converted to NMN). Higher intracellular NAD+ then drives sirtuin deacylase activity and PARP-mediated DNA repair.

// NAMPT PATHWAY BYPASS

The rate-limiting step in endogenous NAD+ synthesis is NAMPT — the enzyme that converts nicotinamide to NMN. NAMPT declines with age and is further suppressed by inflammation and metabolic stress. NMN supplementation bypasses NAMPT entirely, providing the downstream product directly and restoring NAD+ regardless of NAMPT status.

// SIRT1/SIRT3 ACTIVATION

Elevated NAD+ from NMN supplementation activates SIRT1 in metabolic tissues (liver, muscle, adipose) and SIRT3 in mitochondria. SIRT1 deacetylates and activates PGC-1α, driving mitochondrial biogenesis and fatty acid oxidation. SIRT3 deacetylates and activates key TCA cycle enzymes and the antioxidant enzyme SOD2, reducing mitochondrial ROS.

// INSULIN SENSITIVITY & MUSCLE METABOLISM

In the Yoshino 2021 human trial, NMN supplementation (250 mg/day for 10 weeks) significantly improved skeletal muscle insulin signalling, specifically increasing expression of genes involved in muscle remodelling and insulin receptor substrate signalling. This tissue-specific effect confirms NMN acts beyond simple NAD+ elevation to drive functional metabolic improvements.

NMN has stronger human evidence than most longevity compounds. Key human trials: Yoshino et al. (2021, Science) — muscle insulin signalling improvement; Igarashi et al. (2022, npj Aging) — dose-dependent blood NAD+ elevation in older men; Liao et al. (2021) — reduced arterial stiffness in older adults. The main scientific debate is whether NMN is superior to NR (nicotinamide riboside) for raising tissue NAD+. Current evidence slightly favours NMN for muscle NAD+ but the difference may not be clinically significant at typical doses.